Skip to content

Study · Animal study (in vivo) · mouse · 2010

14 results

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL

Journal of applied physiology (Bethesda, Md. : 1985)13 May 2010Cited by 106 (Europe PMC)

PMID20466801 (opens in a new tab)PMCIDPMC2944638 (opens in a new tab)DOI10.1152/japplphysiol.00866.2009 (opens in a new tab)PepBankPUB-20466801
Source linkPubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, mean body weight after ACE‑031 treatment was 16% greater than control.

    In plain wordsIn mice, ACE‑031 increased body weight compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseBody weight
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Body weight difference
    16%
    versus control

    Source sentences

    Summary
    By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05).
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased soleus wet weight by 33% versus control.

    In plain wordsIn mice, ACE‑031 increased soleus muscle weight compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseSoleus wet weight
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Soleus wet weight increase
    33%
    versus control

    Source sentences

    Summary
    By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05).
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased plantaris wet weight by 44% versus control.

    In plain wordsIn mice, ACE‑031 increased plantaris muscle weight compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreasePlantaris wet weight
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Plantaris wet weight increase
    44%
    versus control

    Source sentences

    Summary
    By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05).
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased gastrocnemius wet weight by 46% versus control.

    In plain wordsIn mice, ACE‑031 increased gastrocnemius muscle weight compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseGastrocnemius wet weight
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Gastrocnemius wet weight increase
    46%
    versus control

    Source sentences

    Summary
    By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05).
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased extensor digitorum longus wet weight by 26% versus control.

    In plain wordsIn mice, ACE‑031 increased extensor digitorum longus muscle weight compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseExtensor digitorum longus wet weight
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Extensor digitorum longus wet weight increase
    26%
    versus control

    Source sentences

    Summary
    By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05).
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 did not change soleus fiber-type distribution versus control.

    In plain wordsIn mice, ACE‑031 did not change soleus muscle fiber types compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    No significant changeSoleus fiber-type distribution
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Soleus fiber-type distribution was unchanged with ACE-031 administration, and mean fiber cross-sectional area increased by 22 and 28% (P<0.05) in type I and II fibers, respectively.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased mean soleus type I fiber cross-sectional area by 22% versus control.

    In plain wordsIn mice, ACE‑031 increased type I soleus fiber size compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseSoleus type I fiber area
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Type I fiber area increase
    22%
    soleus

    Source sentences

    Summary
    Soleus fiber-type distribution was unchanged with ACE-031 administration, and mean fiber cross-sectional area increased by 22 and 28% (P<0.05) in type I and II fibers, respectively.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased mean soleus type II fiber cross-sectional area by 28% versus control.

    In plain wordsIn mice, ACE‑031 increased type II soleus fiber size compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreaseSoleus type II fiber area
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Type II fiber area increase
    28%
    soleus

    Source sentences

    Summary
    Soleus fiber-type distribution was unchanged with ACE-031 administration, and mean fiber cross-sectional area increased by 22 and 28% (P<0.05) in type I and II fibers, respectively.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, ACE‑031 increased mean plantaris fiber cross-sectional area by 57% versus control.

    In plain wordsIn mice, ACE‑031 increased plantaris fiber size compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    IncreasePlantaris fiber area
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Measurements

    Fiber area increase
    57%
    plantaris

    Source sentences

    Summary
    In the plantaris, a predominantly type II fiber muscle, mean fiber cross-sectional area increased by 57% with ACE-031 treatment.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice, ACE‑031 did not change soleus MHC isoform transcript levels versus control.

    In plain wordsIn mice, ACE‑031 did not change soleus muscle myosin gene activity compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    No significant changeSoleus MHC isoform transcripts
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Analysis of myosin heavy chain (MHC) isoform transcripts by real-time PCR indicated no change in transcript levels in the soleus, but a decline in MHC I and IIa in the plantaris.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In mice, ACE‑031 decreased plantaris MHC I transcript levels versus control.

    In plain wordsIn mice, ACE‑031 reduced plantaris MHC I gene activity compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    DecreasePlantaris MHC I transcripts
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Analysis of myosin heavy chain (MHC) isoform transcripts by real-time PCR indicated no change in transcript levels in the soleus, but a decline in MHC I and IIa in the plantaris.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In mice, ACE‑031 decreased plantaris MHC IIa transcript levels versus control.

    In plain wordsIn mice, ACE‑031 reduced plantaris MHC IIa gene activity compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    DecreasePlantaris MHC IIa transcripts
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Analysis of myosin heavy chain (MHC) isoform transcripts by real-time PCR indicated no change in transcript levels in the soleus, but a decline in MHC I and IIa in the plantaris.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In mice, ACE‑031 did not change soleus MHC protein isoform proportions versus control.

    In plain wordsIn mice, ACE‑031 did not change soleus myosin protein proportions compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    No significant changeSoleus MHC protein isoform proportions
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, electrophoretic separation of total soleus and plantaris protein indicated that there was no change in the proportion of MHC isoforms in either muscle.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In mice, ACE‑031 did not change plantaris MHC protein isoform proportions versus control.

    In plain wordsIn mice, ACE‑031 did not change plantaris myosin protein proportions compared with vehicle control.

    Peptide
    ACE-031 (ramatercept)
    Outcome
    No significant changePlantaris MHC protein isoform proportions
    Study

    mousen: not reported in source

    8-wk-old C57BL/6 mice
    Comparator
    Vehicle control
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, electrophoretic separation of total soleus and plantaris protein indicated that there was no change in the proportion of MHC isoforms in either muscle.
    1 context sentence
    Summary · context
    In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.